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Abstract
The hepatocyte growth factor (HGF) receptor, Met, has
established oncogenic properties; however, its ex-
pression and function in esophageal adenocarcinoma
(EA) remain poorly understood. We aimed to deter-
mine the expression and potential alterations in Met
expression in EA. Met expression was investigated in
surgical specimens of EA, Barrett’s esophagus (BE),
and normal esophagus (NE) using immunohistochem-
istry (IHC) and quantitative reverse transcriptase
polymerase chain reaction. Met expression, phospho-
rylation, and the effect of COX-2 inhibition on expres-
sion were examined in EA cell lines. IHC demonstrated
intense Met immunoreactivity in all (100%) EA and
dysplastic BE specimens. In contrast, minimal immu-
nostaining was observed in BE without dysplasia or
NE specimens. Met mRNA and protein levels were
increased in three EA cell lines, and Met protein was
phosphorylated in the absence of serum. Sequence
analysis found the kinase domain of c-met to be wild
type in all three EA cell lines. HGF mRNA expression
was identified in two EA cell lines. In COX-2–over-
expressing cells, COX-2 inhibition decreased Met
expression. Met is consistently overexpressed in EA
surgical specimens and in three EA cell lines. Met
dysregulation occurs early in Barrett’s dysplasia
to adenocarcinoma sequence. Future study of Met
inhibition as a potential biologic therapy for EA is
warranted.
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Introduction
Esophageal adenocarcinoma (EA) is a highly aggressive
malignancy with propensity for early local invasion and
systemic metastases. The incidence of EA is increasing
rapidly and, currently, EA represents the most common
histologic type of esophageal cancer in the United States
[1,2]. Despite advances in the diagnosis and treatment
of the disease, the overall 5-year survival remains approx-
imately 14% [3]. Molecular events responsible for the
development of EA that contribute to such a malignant
phenotype are poorly understood. Thus, elucidation of these
molecular alterations is important to facilitate the identification
of key molecular targets and diagnostic markers.
Met is a transmembrane tyrosine kinase receptor encoded
by the c-Met proto-oncogene (p190MET) and is expressed in
most epithelial and endothelial cells. The receptor is phospho-
rylated upon binding with high affinity to the ligand hepatocyte
growth factor (HGF), also known as scatter factor [4–7]. HGF
is produced mostly by mesenchymal cells, acting as a para-
crine factor on epithelial tissues [8]. Met receptor activation has
mitogenic, motogenic, and angiogenic cellular effects, and
has been implicated in tumor development and progression
[5,9–11]. Met also appears to have an important role in the
healing of gastric and esophageal ulcers through interactions
with cyclooxygenase-2 (COX-2) enzymes. Inhibition of COX-2
has been shown to downregulate Met expression in gastric
ulcer healing and, importantly, to reduce the frequency of
malignant progression of Barrett’s esophagus (BE) [12–14].
The intracellular events and pathways involved following
Met activation are complex and only partially understood. The
signaling cascade is known to be associated with phosphatidyl-
3-kinase, Ras-MAP kinase, STAT, PLC-g, and other proteins
related to established cell proliferation and antiapoptotic path-
ways [15]. Activation of the Met/HGF pathway can result in
cancer cell proliferation, resistance to apoptosis, and increased
production of serine proteases, promoting tumor growth, cell
motility, and invasion [8,16]. In addition, Met has also been
shown to directly inhibit apoptosis through sequestration of
the Fas receptor in murine hepatocellular carcinoma [17].
The overexpression of Met and/or its ligands has been
shown to contribute to the development and progression of
different malignancies including lung, colorectal, gastric,
breast, prostate, thyroid, pancreas, and oral squamous cell
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carcinomas [18–22]. Studies have demonstrated the over-
expression of Met and HGF in esophageal squamous cell
carcinoma [22–24], but only one study has [25] partially
evaluated the expression patterns of the Met receptor and
HGF in EA.
In this study, we characterized for the first time the
expression patterns of Met in human EA tissue samples.
We also examined three EA cell lines for in vitro studies of
Met expression and function. We demonstrate that Met is
markedly and frequently overexpressed in EA, and this




All human tissues were obtained through protocols ap-
proved by the University of Pittsburgh Institutional Review
Board. All archived EA specimens from a 10-year time per-
iod were identified and retrieved. Patients who had received
preoperative radiation therapy were excluded. Specimens
were also excluded following histologic review if the tumor
sample did not represent at least 50% tumor cellularity, or if
the esophageal squamous epithelium specimen contained
any malignant cells. The resulting study group represented
matched specimens from 26 patients.
For experiments requiring fresh tissues, specimens of
patients undergoing esophagectomy at the University of
Pittsburgh were prospectively collected as part of an institu-
tional esophageal cancer risk registry. Samples of fresh
tissues corresponding to esophageal tumor, normal distant
esophagus, and areas of BE (when available) were obtained
at the time of surgery, immediately frozen in liquid nitrogen,
and stored at 80jC until analyzed. We randomly selected
10 matched cancer tissue specimens and normal esopha-
geal specimens for our analysis.
In Vitro Cell Culture
Three human EA cell lines (FLO-1, SEG-1, and BIC-1)
were used for in vitro studies. An SV-40 immortalized
squamous epithelial cell line (HET-1A) served as a control.
Cell lines were maintained in Dulbecco’s modified essential
medium (DMEM; Gibco-BRL, Rockville, MD) containing 10%
FBS and 1% penicillin/streptomycin. For experiments eval-
uating the phosphorylation status of Met, treatment groups
included standard culture conditions, serum starvation for
24 hours, and serum starvation prior to a 30-minute treat-
ment with recombinant HGF at a concentration of 50 ng/ml
(R&D Systems, Minneapolis, MN). SEG-1 (COX-2 –
expressing) and BIC-1 (COX-2–negative) cells were incu-
bated in the presence or absence of a selective COX-2
inhibitor (NS-398 at 10–100 mg) for 18 hours.
RNA Extraction and Quantitative Real-Time Reverse
Transcriptase Polymerase Chain Reaction (RT-PCR)
RNA extraction was performed on EA cell lines and
esophageal tissue sections (10 10 mm sections) using an
RNAeasy kit (QIAGEN, Valencia, CA). All samples were
DNAse-treated. Primers and probes were designed using
the Primer Express software (Applied Biosystems, Foster
City, CA) to flank an intronic sequence. RT reactions were
performed in the iCycler PCR instrument (Bio-Rad, Hercules,
CA) using specific RT primers for HGF, Met, and an endog-
enous control gene [either b-glucurosidase (b-Gus) or 18S
ribosomal RNA (18S)]. All RT reactions were performed in
duplicates with RNA inputs of 1 and 250 ng per sample, using
Superscript II reverse transcriptase as described previously
[26]. Five microliters of the first-strand cDNA was amplified
as a separate step in a 96-well plate on the TaqMan ABI
7700 instrument (Applied Biosystems) using specific Met,
b-Gus, and/or 18S primer sets and a florescent-labeled
oligonucleotide for signal detection (Table 1). The conditions
for the PCR reactions were 95jC for 12 minutes followed
by 40 cycles of denaturation (95jC for 30 seconds) and
annealing/extension (60jC for 1 minute) steps. Nonreverse
transcription controls (no-RT enzyme) were performed for
each RNA sample and no-template controls were included
on each PCR plate. Amplification plots were generated and
the Ct value (cycle number at which fluorescence reaches
threshold) recorded. A calibrator RNA sample was included
in each batch of RT-PCR to adjust for interplate variability,
and relative expression of Met and HGF was calculated
using the DCT approach as described previously [27]. In
the COX-2 inhibition study, b-Gus was found to be regulated
by NS-398 and the Met levels were therefore normalized to
those of 18S instead.
Immunohistochemistry (IHC) in Tissue Specimens
Five-micron sections of formalin-fixed esophageal speci-
mens were analyzed for Met protein expression by IHC.
Rabbit anti–Met polyclonal antibody (SC-161; Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) was used at a dilution
of 1:100 for IHC staining. Biotinylated anti–rabbit IgG was
used as the secondary antibody and then stained with the
Fuchsin Substrate System (DAKO, Carpinteria, CA). Anti-
body specificity was confirmed by primary antibody delete
controls. A specimen of hepatocellular carcinoma metastatic
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to the lung, which provided intense but cancer cell–specific
staining, served as a positive control. IHC slides were
reviewed by a pathologist experienced in esophageal malig-
nancies. A scoring system based on the percentage of tumor
cells staining per slide was created. The scoring system had
a range of 0 (no staining) to 3 (100% of tumor cells staining
for Met). Reported values are the average score per sample
(multiple blinded slides for each sample were independently
reviewed). For grading BE samples, the intensity was eval-
uated for a representative area for metaplasia, low-grade
dysplasia (LGD), and high-grade dysplasia (HGD), and
graded from 0 to 3.
Met Immunoblotting
Protein extraction was performed from total cell lysates
as previously described [28]. Proteins were resolved on 8%
polyacrylamide gels. Following protein transfer to nitrocellu-
lose membranes, Met immunoreactivity was examined using
anti–Met polyclonal rabbit antibody (1:10,000 dilution of
SC-161; Santa Cruz Biotechnology, Inc.) or an anti–c-Met
phospho-specific antibody (BioSource International, Cama-
rillo, CA), and a peroxidase-labeled secondary antibody.
Enhanced chemiluminescence (Pierce, Rockford, IL) was
used to detect immunoreactive proteins.
Subcellular Localization of Met, Determination of
Phosphorylation Status, and Fas–Met Association
Experiments: IP and Laser Scanning Confocal Microscopy
Cells were plated on uncoated glass cover slips, allowed
to adhere for 48 hours, and subsequently fixed in 2%
paraformaldehyde. After blocking nonspecific antibody bind-
ing with a 1:20 dilution of rabbit serum, cells were stained
with rabbit polyclonal anti–Met antibodies (1:2500 dilution of
SC-161; Santa Cruz Biotechnology, Inc.) and detected with
appropriate fluorescent label– tagged secondary antibodies
(Jackson Immunolaboratories, West Grove, PA). Specimens
treated by omitting the primary antibody served as controls
for nonspecific staining. For experiments examining potential
Fas–Met interactions, anti-Fas antibodies (1:5000 dilution of
clone CH-11; New England Biolaboratories, Waltham, MA)
were included in the primary labeling step. Staining was
assessed and images were obtained by laser scanning
confocal microscopy (Leica Microsystems, Inc., Bannock-
burn, IL). Immunofluorescence staining was performed as
above using two unique phospho-Met–specific antibodies
independently (Tyr 1349 and Tyr 1234/1235; Cell Signaling
Technology, Beverly, MA).
For immunoprecipitation of Met, protein lysis buffer
(20 mM Tris–Cl pH 7.5, 150 mM NaCl, 2 mM EDTA, 1%
Triton-X, 2.5 mM Na-pyrophosphate, and 1 mM glycerol
phosphate) with protease and phosphatase inhibitors was
added directly to cell cultures and incubated on ice for
15 minutes. Cell lysates were incubated for 1 hour at 4jC
with protein A beads. Following removal of the beads by
centrifugation, anti-Met antibody (clone 25H2; Cell Signaling
Technology) was added and the lysates incubated over-
night at 4jC, following which another aliquot of protein A
beads was added to each tube and mixed for 4 hours at
4jC. Following five washes, precipitated protein/protein A
beads were pelleted and resuspended in 20 ml of 2 sample
buffer and the proteins resolved on 8% polyacrylamide gel.
Total lysate from the SEG-1 cell line was included as a
positive control. Following membrane transfer, rabbit anti-
Met (SC-161; Santa Cruz Biotechnology, Inc.) was used to
detect the precipitated Met proteins. Coprecipitation of Fas
was evaluated using rabbit anti-Fas antibodies (Apo-1-3
clone; Kamiya, Seattle, WA). Peroxidase-labeled secondary
antibodies and enhanced chemiluminescence (Pierce) were
used for detection.
c-met Sequence Analysis
As previously described [28], total RNA was isolated
from SEG-1, BIC-1, FLO-1, and HET-1A cell lines and
reverse-transcribed. PCR amplification of the tyrosine kinase
catalytic domain (bases 3311–4311, accession no. NM
000245) of Met mRNA from the RT product was performed
using the forward primer 5V-AGTGCAGTATCCTCTGACA-
GAC-3V and the reverse primer 5V-GTCCATGTGAACGC-
TACTTATG-3V. Amplification products were purified using
the Promega Wizard DNA purification kit (Promega, Madi-
son, WI) and sequenced using the same primers by auto-
mated sequencing at the DNA sequencing facility at the
University of Pittsburgh. A nested set of sequencing primers
(5V-ATTCACTGTGCTGTGAAATCC-3V and 5V-GCGCATT-
TCGGCTTTAGGGTG-3V) was necessary to obtain high-
quality sequence data.
Statistical Analysis
The IHC scores determined for multiple slides from each
specimen were averaged. The comparison of matched tis-
sue specimens [EA and normal esophagus (NE) from each
patient] from 26 patients was tested with the signed rank
test. To examine the hypothesis that Met expression reflects
the progression of BE to EA, the average IHC scores of
patients with BE were compared to the scores of EA patients
with the Jonckheere-Terpstra test. This test is sensitive to
differences between groups in which the difference reflects
the upward or downward trend among the groups. Specific
comparison of the IHC scores between two independent
groups was conducted with the Wilcoxon test.
Results
Overexpression of Met mRNA and Protein in EA Specimens
We analyzed surgical specimens from 26 patients un-
dergoing esophagectomy for EA. IHC staining to detect
Met protein expression in matched samples of EA and
NE revealed consistent and intense anti-Met immunostain-
ing specific to the cancer cells (Figure 1D) compared to
nearly absent staining in NE samples and stromal tissues
(Figure 1A). Met protein appeared to localize to the cell
surface as well as cytoplasm of the malignant cells, although
this assessment must be taken in the context of the resolu-
tion limitations of light microscopy. NE tissue had faint IHC
staining in a heterogeneous pattern. The semiquantitative
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grading of IHC staining demonstrated a median IHC score of
2.49 on EA specimens. In comparison, the median IHC score
for normal control tissue was 0, with 69% of specimens
scoring zero in every cross section examined. The IHC
scores were significantly higher in EA when compared to
matched NE samples, confirming that Met protein is overex-
pressed in human EA specimens (P < .0001, Wilcoxon
signed rank test) (Figure 2A).
Met Overexpression Occurs Early in Barrett’s Metaplasia–
Dysplasia–Adenocarcinoma Sequence
To determine if Met overexpression occurs at an early
stage in the progression from BE to EA, IHC was performed
in eight tissue specimens of BE with varying degrees of
dysplasia. Intense Met staining was observed throughout
regions of HGD, but this staining was more heterogeneous
when compared to the staining seen in EA specimens
(Figure 1, A–C). Met IHC of specimens with dysplasia
demonstrated a direct correlation between the intensity of
Met staining and the degree of dysplasia. Met staining was
minimal in areas of BE (Figure 1, A and B), but Met staining
was stronger in areas of BE with LGD and HGD (Figure 1,
B and C). There was a statistically significant increase in
Met IHC staining as the degree of dysplasia progressed
from BE to EA (P < .0002, Jonckheere-Terpstra test)
(Figure 2B). Met IHC scores were significantly higher in BE
with LGD when compared to BE without dysplasia, suggest-
ing that Met overexpression is present early in the metapla-
sia–dysplasia–adenocarcinoma sequence (P = .0242,
Wilcoxon test). Neither HGD nor EA was significantly greater
than LGD. These findings of a correlation of Met overexpres-
sion with the development of cellular alterations character-
istic of dysplasia in BE suggest that Met overexpression can
occur as an early event in EA tumorigenesis.
To investigate the mechanism of Met overexpression in
EA, we prospectively collected 10 surgical specimens for
the evaluation of Met mRNA expression levels. Two of
these samples were subsequently excluded due to inade-
quate percentage tumor representation. Quantitative reverse
transcriptase polymerase chain reaction (QRT-PCR) analy-
sis of EA specimens and matching normal esophageal
tissues demonstrated Met overexpression in five of eight
EA samples examined relative to control squamous epithe-
lium (Figure 3). Met mRNA was two-fold higher in EA
Figure 1. Met IHC in esophageal surgical specimens. Met-specific staining appears red. (A) Met staining in specimen of NE with Barrett’s intestinal metaplasia.
Note the lack of staining in the normal squamous epithelium (SE) and even in BE (original magnification,100). (B) Met staining in specimen of BE with dysplasia.
Met staining is minimal in areas of LGD, but the staining becomes intense in areas of Barrett’s with HGD identified by nuclear atypia, and the loss of cellular
organization and goblet cells (original magnification,100). (C) High-power view of Met staining in a specimen of BE with dysplasia (original magnification,400).
There is minimal Met staining in the proliferative zone of areas of LGD, but diffuse intense staining in areas of HGD. (D) Met staining in specimen of EA (original
magnification,400). An area of HGD is also present within this field.
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(mean expression 0.38) when compared to NE samples
(mean expression 0.20) (P = .004, Mann-Whitney U test)
(Figure 3). Taken together, our data suggest that Met
protein overexpression in a subset of EA surgical speci-
mens is due to increased Met mRNA. Posttranscriptional
mechanisms in other EA tumors are likely responsible for
this overexpression.
Met Is Overexpressed at the mRNA and Protein Levels in
EA Cell Lines
We next aimed to verify that three EA cell lines were
appropriate in vitromodels of Met overexpression in EA. Met
mRNA expression in three EA cell lines (SEG-1, BIC-1, and
FLO-1) was analyzed. The SV-40 immortalized squamous
esophageal cell line (HET-1A) served as a control. Met
mRNA expression in FLO-1, SEG-1, and BIC-1 EA cell lines
was on the order of 10,000-fold higher than the control cell
line HET-1A (Figure 4A) as determined by QRT-PCR. Met
mRNA was not detectable in our no-template and no-RT
controls, excluding the possibility of sample contamination
or genomic DNA amplification. These results demonstrated
that Met mRNA is abundantly expressed in all three EA
cell lines.
We also examined a potential coexpression of the ligand
HGF by these cells. RNA analysis demonstrated HGF (Met
ligand) expression in BIC-1 and SEG-1 cells, but not in the
FLO-1 or HET-1A cell line (Figure 4A). These findings
suggest, but do not confirm, that Met may be activated in
these two EA cell lines through an autocrine loop.
To verify the presence of mature, full-length Met protein
expression in the cell lines, immunoblot analysis of total
cellular protein lysates with anti-Met antibodies was per-
formed. These results demonstrated that all three EA cell
lines, but not the control squamous epithelial cell line HET-
1A, expressed Met protein in its mature 140-kDa form and
in its 170-kDa precursor (Figure 4B). Of note, Met expres-
sion in FLO-1 was predominantly in its mature 140-kDa
form. Taken together, these data demonstrate that Met
expression in the EA cell lines appears consistent with that
observed in the surgical specimens, and these cell lines
are an adequate model for in vitro experiments to further
evaluate Met expression and function in EA.
The Three EA Cell Lines Exhibit Constitutive Met
Phosphorylation in the Absence of HGF Stimulation That
Is Increased Following HGF Stimulation
Our next objective was to evaluate the phosphorylation
status of Met in these cell lines (Figure 5). Immunofluores-
cence using anti–phospho-Met–specific antibodies demon-
strated staining for phosphorylated Met localized to the cell
surface of all three EA cell lines that had been serum-
starved. Treatment of the SEG-1 and BIC-1 cell lines with
recombinant HGF did not result in increases in phospho-
Met–specific staining (data not shown) or characteristic
morphologic changes (scatter effect). Immunodetection of
phosphorylated Met was also observed in serum-starved
FLO-1 cells that do not express HGF mRNA. In this cell line,
treatment with HGF did result in subtle morphologic changes
(scattering) and an appreciable increase in staining for
phosphorylated Met (Figure 5A). The phosphorylation status
Figure 2. Anti-Met IHC scores in EA and BE with and without dysplasia. (A) Met (IHC) scores for matched EA and NE tissue samples. The IHC was interpreted by
an expert pathologist and graded using a standard score based on the staining intensity and percentage of field stained with a score ranging from 0 to 3. IHC scores
were significantly higher in EA when compared to matched NE samples (P < .0001, Wilcoxon signed rank test). (B) Met IHC score for BE, LGD, HGD, and EA.
There was a statistically significant increase in Met IHC staining as the degree of dysplasia progressed to adenocarcinoma (P < .0001, Jonckheere-Terpstra test).
Met IHC scores were significantly higher in BE with LGD when compared to Barrett’s metaplasia, suggesting that Met overexpression is present early in the
metaplasia–dysplasia–adenocarcinoma sequence (P = .0242, Wilcoxon exact test).
Figure 3. Met mRNA expression in specimens of EA and NE. Met mRNA
expression was analyzed in 10 control esophageal samples and in eight EA
samples. Met mRNA was significantly higher in EA (mean expression 0.3768)
when compared to matching control NE (mean expression 0.20097)
(P = .004, Mann-Whitney U test).
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of Met was also evaluated by Western blot analysis using
a phosphorylated specific [pYpYpY1230/1234/1235] anti –
c-Met polyclonal antibody (BioSource International). Phos-
phorylated Met was detected in FLO-1, BIC-1, and SEG-1
cells following 24 hours of serum starvation, but not in the
A549 lung adenocarcinoma cell line serving as a control
(Figure 5B). HGF treatment (50–100 ng/ml) resulted in
phosphorylation of Met in the A549 cell line and increased
phosphorylation of Met in the three EA cell lines.
Thus, we concluded that Met is phosphorylated in the
absence of serum or exogenous HGF in all three EA cell lines
and this activation can be further stimulated by the addition
of ligand. Taken together, these data suggest that Met is
autophosphorylated in SEG-1 and BIC-1 cells, and this may
occur through HGF expression resulting in autocrine activa-
tion of the receptor. Ligand-independent phosphorylation of
Met occurs in the FLO-1 cell line.
A number of mutations of the c-met locus, most involving
the kinase domain of the protein, have been shown to
increase the activity of the receptor by mechanisms that
are not well clarified [16,29]. We hypothesized that the
FLO-1 cell line might contain an activating mutation that
could explain the above findings. DNA sequence analysis
of the kinase domain of Met in SEG-1, BIC-1, and FLO-1 was
performed to identify potential activating mutations in the Met
coding sequence. However, sequence analysis of cDNA
generated from the SEG-1, FLO-1, and BIC-1 cell lines did
not reveal any mutations compared to the wild-type se-
quence. Thus, the mechanism of Met autophosphorylation
in FLO-1 cells remains unclear.
Met Protein Expression Localizes to the Cell Membrane and
Is Not Associated With Fas Receptor
To determine if the Met receptor localizes to the cell
surface in EA, we analyzed Met protein localization in the
EA cell lines by immunofluorescent laser scanning confocal
microscopy. These studies demonstrated that, as expected,
Met protein localizes predominantly on the cell membrane
with a smaller fraction of protein observed in a perinuclear
reticular pattern suggestive of localization to the ER or
endosomes (Figure 6A). Because others have reported that
Met shares a protein–protein interaction with the death
receptor Fas (CD95) in murine hepatocellular carcinoma
[30], we sought to determine if this association could be
responsible for the lack of cell surface expression of Fas and
resistance to Fas-mediated apoptosis in EA that we have
previously reported [28]. However, dual-labeled immuno-
fluorescence to Fas and Met did not suggest that there was
colocalization of the two proteins at the cell surface. In addi-
tion, immunoprecipitation experiments failed to demonstrate
that Met and Fas proteins were associated (Figure 6B).
Thus, we were not able to demonstrate Fas–Met interac-
tions either by imaging or immunoprecipitation. In contrast to
Fas, Met appears to be effectively trafficked to the cell
surface in the EA cell lines examined.
Selective COX-2 Inhibition Downregulates Met Expression
in EA Cell Lines
Recent reports have demonstrated that gastric ulcer
patients and mouse models of esophageal ulceration suffer
from delayed healing when treated with COX-2 inhibitors due
to significant downregulation of Met at the ulcer’s edge [12].
This prompted us to investigate whether pharmacologic
COX-2 inhibition can result in reduction in Met expression
in EA. We evaluated Met mRNA and protein expression
after COX-2 inhibition in one EA cell line with no COX-2
expression (BIC-1) and one with marked COX-2 expression
(SEG-1) [31]. Cells were treated for 48 hours with celebrex
[25] or NS-398 (100 mM) at doses that result in selective
COX-2 inhibition. Cells were also treated with PMA (100),
a known inducer of Met, through activation of protein kinase
C as a positive control. We observed a significant dose-
dependent reduction (60% maximum decrease compared to
control) of Met mRNA in SEG-1 cells but not in the COX-2–
negative BIC-1 cells (Figure 7). At the protein level, a marked
reduction in expression was observed following treatment
with celecoxib and NS-398 in the SEG-1 cell line, but not in
the BIC-1 cell line. PMA treatment increased Met protein
expression in both cell lines. These data suggest that COX-2
overexpression may contribute to the Met overexpression
Figure 4. Met mRNA expression in EA and NE cell lines. (A) Met and HGF
mRNA relative expression (log scale) in HET-1A cells, an immortalized
human squamous epithelial cell line serving as a control, and three human EA
cell lines (BIC-1, FLO-1, and SEG-1) as determined by QRT-PCR. The
mRNA expression is relative to the control endogenous gene -Gus to adjust
for mRNA integrity and quantity. (B) Western blot analysis for Met protein
expression in EA cell lines (BIC-1, FLO-1, and SEG-1) and the control
epithelial cell line HET-1A. Marked overexpression of Met protein (140 kDa
mature form and 170 kDa Met precursor) was evident in all three EA cell
lines, but not in the control. a-Actin was used as loading control.
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in some EA tumors, but Met overexpression can occur inde-
pendently of COX-2 overexpression (COX-2–negative BIC-
1 cells overexpress Met).
Discussion
The HGF/Met tyrosine kinase receptor pathway has been
suggested by others as an important contributor to malignant
phenotype by increasing cell proliferation, inhibiting apopto-
sis, and promoting cell migration and invasion and, thus,
metastasis [5,8,10,32]. In this study, we demonstrate for the
first time that Met is markedly and consistently overex-
pressed in EA. This overexpression was evident at the
protein level in 26 of 26 surgical specimens evaluated by
IHC as well as in three different EA cell lines. We have shown
that Met protein overexpression can occur through an in-
creased expression of Met mRNA, but our data also suggest
that other mechanisms may also lead to this phenotype. Met
overexpression seems to be an early event in the develop-
ment of EA, as we identified Met protein overexpression in
regions of dysplasia in Barrett’s epithelium. This suggests
that dysregulation of the HGF/Met pathway could have a
contributing role in the malignant progression of BE to EA.
That Met protein is universally overexpressed in EA and that
this overexpression is already present in precursor lesion BE
suggests that, similar to other tyrosine kinases, theMet recep-
tor may prove to be an attractive target for chemoprevention
or chemotherapy against EA. Based on our findings, future
studies focusing on inhibition of this pathway with anti-Met–
directed therapy in EA are clearly warranted.
We also report our characterization of Met expression in
three EA cell lines and in vitro studies aimed at eliciting
potential mechanisms that could be responsible for Met
alterations in EA. We have shown that Met is constitutively
phosphorylated in all three cell lines, and discovered that two
of these cell lines express HGF mRNA, suggesting that the
Met receptor may be activated through an autocrine loop in
EA. We initially suspected that Met phosphorylation in the
absence of serum or exogenous HGF in the FLO-1 cell line,
combined with the finding that the majority of Met protein was
cleaved to the mature form in this cell line, was due to an
activating mutation of the Met sequence in FLO-1 as had
been reported in other tumor cell lines [29]. Sequence
analysis, however, did not identify a mutation. The absence
of an activating mutation in kinase domain of these three cell
lines does not exclude the possibility that mutations are
present elsewhere in the full coding sequence of the c-Met
gene in the FLO-1 cell line or in some cases of EA. Another
alternative is that ligand-independent activation of Met may
occur in the FLO-1 cell line, as others have suggested that
overexpression of the receptor can result in heterodimeriza-
tion and autoactivation of the receptor kinase [32]. Finally,
our immunoblot data showing that the majority of Met pro-
teins in the FLO-1 cell line is cleaved to the mature form of
Figure 5. Constitutive phosphorylation of the Met receptor in SEG-1, FLO-1, and BIC-1 cells. (A) Laser scanning confocal microscopy of FLO-1 cells serum-starved
for 24 hours, or serum-starved prior to treatment with 50 nM HGF. Cells were stained with anti –phospho-Met–specific antibodies. Cell surface phospho-Met is
detected in the serum-starved FLO-1 cells. Treatment with HGF resulted in increased intensity of phospho-Met staining on the cell surface in the FLO-1 cell line
and subtle morphologic changes (scattering). Original magnification,  600. (B) Immunoblots using a phospho-Met–specific antibody. The A549 lung
adenocarcinoma cell line served as a positive control for Met phosphorylation in response to HGF treatment. Phosphorylated Met is observed in all three EA cell lines
grown in serum-starved conditions, but not in the A549 cell line. HGF treatment resulted in phosphorylation of Met in the A549 cell line and increased phosphorylation
of Met in all three EA cell lines.
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the receptor may suggest that increased proteolytic cleavage
of Met to the mature form of the protein could contribute to
the observed autophosphorylation.
One limitation of this study is that because we only
examined a single population cell culture model, the inter-
actions of Met with other cells and proteins in the tissue
stroma could not be examined. We would have liked to
examine the effects of Met inhibition and thus have been
able to examine Met function in EA in an in vivo model
where the epithelial–stromal interactions are intact, but a
highly specific, small-molecule Met inhibitor has only recently
been reported and is currently not generally available for
research purposes [33].
A potential explanation for the frequent overexpression of
Met in EA may be the role of HGF/Met pathway in the healing
process of esophageal and gastric ulcerations [12]. It is well
established that processes that chronically injure the esoph-
ageal mucosa (i.e., GERD) are risk factors for the develop-
ment of dysplasia and, eventually, esophageal cancer. The
interaction of Met with prostaglandins has been reported,
particularly in tissue inflammation and wound healing [12–
14]. In our study, we demonstrated that COX-2 inhibition
downregulates the mRNA and protein expression of Met in
the COX-2–overexpressing EA cell line SEG-1. This effect
was specific because the BIC-1 cell line (COX-2–negative)
showed no change in Met mRNA or protein expression with
Figure 6. Cellular localization of Met in EA and lack of colocalization or protein –protein interaction with the death receptor Fas (CD95). (A) Laser scanning confocal
microscopy of SEG-1 cells. Perinuclear autofluorescence is visualized in primary antibody delete controls. Met immunofluorescence labeling reveals predominantly
cell surface localization of the protein. Dual-labeled immunofluorescence for Fas (red) and Met (green) does not suggest significant colocalization of the two proteins
(yellow). Original magnification, 600. (B) Immunoprecipitation experiment to determine potential Fas–Met interactions in the EA and HET-1A cell lines. Mouse
monoclonal Met antibody was used to immunoprecipitate the Met receptor, and associated proteins and immunoblots of the precipitated proteins were performed
using anti-Met or anti-Fas rabbit polyclonal AB. Total protein lysate from SEG-1 cell lines (CTRL) was used as a positive control for Met and Fas signals. No protein–
protein interaction between Fas and Met was observed.
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COX-2 inhibition. Thus, Met overexpression in EAmay follow
from COX-2 overexpression, but also may occur indepen-
dently of COX-2 overexpression. Further studies are needed
to further clarify the relationship of COX-2 and Met expres-
sion in EA. Our results do support the theory that one
mechanism through which COX-2 inhibition negatively
affects tumor progression is due to this concomitant down-
regulation of Met.
Finally, Met protein has been shown to interact and
sequester Fas receptors at the cellular membrane in murine
hepatocellular carcinoma cell lines, causing resistance to
Fas-mediated apoptosis [30]. Because our EA cell lines are
known to be resistant to Fas-mediated apoptosis [28], we
examined whether this mechanism of Fas sequestration
was present in the EA cell lines. However, no Fas–Met
interaction was demonstrable in our EA cell lines by either
immunocoprecipitation of the two receptors or dual-labeled
immunofluorescence and laser scanning confocal micros-
copy. We suspect that this finding is due to the fact that Met
is phosphorylated in serum-free conditions in these cell
lines, resulting in disassociation of Met and Fas as has
been reported by others [34].
Summary
Met expression is altered in EA with marked and consistent
overexpression of the proto-oncogene Met. This over-
expression was observed in BE with HGD and EA. Met is
also overexpressed significantly in EA cell lines and Met
mRNA expression can be downregulated with COX-2 inhi-
bition, suggesting an interaction in these two pathways in
some EAs. Our results suggest that Met would be an
attractive target for molecular therapy with tyrosine kinase
inhibition. Additional studies of Met overexpression, function,
and inhibition in EA are clearly warranted.
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